Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I'm not exactly sure on the date they updated their website.
Timeline for BPX-04
Here is when the trial started.
https://www.prnewswire.com/news-releases/biopharmx-initiates-phase-2b-trial-of-bpx-04-for-rosacea-300729730.html
Estimated Study Completion Date: May 27, 2019 - August 17, 2019
https://clinicaltrials.gov/ct2/show/NCT03667222?term=biopharmx&draw=1&rank=1
BPX-04 Update!
The primary efficacy endpoint from this study is change in Investigator’s Global Assessment (IGA) of rosacea at 12 weeks. The secondary efficacy endpoint is change in facial lesion count from baseline at 12 weeks. The preliminary data obtained to date suggest a positive effect on rosacea lesions. Of the 15 subjects that have completed 12 weeks of treatment in the study, 100% have IGA scores of clear (0) or almost clear (1), compared to their baseline scores of moderate (3) or severe (4). Investigators also observed a 93% reduction in total inflammatory lesions from baseline to week 12 in the same subjects who have completed the 12-week study.
Based on these results, the company expects to pursue additional research to evaluate the efficacy of BPX-04 in rosacea.
https://www.biopharmx.com/pipeline/bpx-04-rosacea/
Estimates, can't trust em. Wait for the company to announce the ER date.
Hasn't been announced yet.
A run to peak a bit above $4.50 coming?
Maybe touch that 50(MA)?
I'm in, let's get it!
Ready for a turnaround? Bottom in? Chart worth looking at.
Foamix Announces Appointment of Matt Wiley as Chief Commercial Officer
Nov. 27, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today announced the appointment of Matt Wiley as Chief Commercial Officer. In this newly created position, Matt will be responsible for the development and execution of commercial strategies of the company’s product portfolio, including the planned launches of FMX101 for acne and FMX103 for rosacea.
“Matt has an exceptional commercial record in pharmaceuticals and brings valuable experience and depth of knowledge in marketing, market access, and product launches,” said David Domzalski, Chief Executive Officer of Foamix. “He will be a key addition to the Foamix team as we pursue regulatory filings for our lead candidates FMX101 for acne and FMX103 for rosacea and prepare to launch these products. We look forward to benefitting from his experience and insights as we transition to becoming a fully integrated, commercial stage company.”
Matt Wiley joins Foamix with more than 20 years of commercial experience across a broad range of specialty pharmaceutical categories. Prior to joining Foamix, Mr. Wiley spent six years at Jazz Pharmaceuticals. Most recently he was Vice President of Marketing and Business Unit Lead for the company’s sleep disorder portfolio. During this period, he led the efforts to unlock additional value of the company’s largest business unit, including Jazz Pharmaceuticals’ most successful product, Xyrem®, which grew fivefold to over $1 billion in annual sales. Prior to Jazz, Mr. Wiley was Vice President of Marketing at Azur Pharma where he was responsible for all brand management across the company’s women’s health and CNS businesses before the company was acquired by Jazz in 2012. Earlier in his career, he held roles of increasing responsibility in sales, marketing, and training at Guilford/MGI Pharma, Salix, Cephalon, and Rhone-Poulenc Rorer. He holds a bachelor’s degree in English from Syracuse University.
“Joining Foamix is a tremendous opportunity,” said Matt Wiley, newly appointed Chief Commercial Officer of Foamix. “I am enthusiastic about the commercial prospects for both FMX101 and FMX103 and their potential to address serious unmet needs in acne and rosacea. I look forward to leading the efforts to bring these products to market and contributing to Foamix’s success.”
Earnings Boost?
Typically this ticker doesn't move on their earnings report, although this time we should see a boost.
Take in consideration the cutbacks CEO Tierney has been making. This company has been burning around 4.3M each quarter. At the closing of this quarter, we've seen large paycheck cuts from payroll, a new R&D location around half the cost of the last location, and I'm sure some other undisclosed info that should give our share price a kick in the pants that it n deserves. I predict we see a new burn rate of around the low to mid 3Mil range.
Tierney has been quietly working hard on correcting the past damage! I'm looking forward to seeing this next earnings report. Stay alert!
BiopharmX Acne Symposium and NDR
Solebury Trout Annual 1x1 Management Access Event
San Francisco, CA, United States, January 7 – January 10, 2019
Event Link
Solebury Trout provides investor relations, corporate communications and market access.
"The combination of an established corporate communications practice, market access abilities and capital markets advisory platform gives Solebury Trout an unmatched ability to reach key stakeholders and maximize shareholder returns for life sciences companies at every stage of development."
Jonathan Fassberg, Co-CEO of Solebury Trout
Solebury Trout provides investor relations, corporate communications and market access. Over more than 20 years and 500 engagements in life sciences, the company has introduced clients to a unique, highly-specialized and sophisticated investor and sell-side analyst base and hosted hundreds of well-attended conferences, R&D days and thought leader events.
"Solebury Trout has been a leader in providing strategic investor relations and market access to life sciences companies for more than two decades. Together we are well-positioned to bring comprehensive investor relations and corporate communications services to leading life sciences companies, helping them achieve their ambitious goals of bringing innovative new treatments to patients in need."
Brad Miles, founder of BMC Communications
Credit: Chaka_Is_My_Hero
The Company expects to receive aggregate gross proceeds of up to approximately $3.7 million from the cash exercise of the Existing Warrants by the Exercising Holders.
The Exercising Holders and the Company agreed that the Exercising Holders would cash exercise up to 26,666,666 shares of Common Stock underlying such Existing Warrants (the “Exercised Shares”).
In order to induce the Exercising Holders to cash exercise the Existing Warrants, the Exercise Agreements (i) amend the Existing Warrants to reduce the exercise price per share of the Existing Warrants to $0.14 (provided that the Existing Warrants are exercised prior to February 28, 2019, otherwise such exercise price shall remain $0.25 per share).
New Warrants to be issued on a share-for-share basis in an amount equal to the number of shares underlying Existing Warrants that are cash exercised by February 28, 2019. The New Warrants are exercisable after the six-month anniversary of issuance and terminate on the 30-month anniversary following their issuance. The New Warrants have an exercise price per share of $0.164.
BioPharmX FORM 8-K
Entry into a Material Definitive Agreement.
On November 24, 2017, BioPharmX Corporation (the “Company”) issued warrants to purchase up to an aggregate of 73,500,000 shares of Common Stock (the “Existing Warrants”) with an exercise price per share of $0.25. The Existing Warrants were immediately exercisable and set to expire upon the earlier of (1) the twenty-first trading day after the Company issues a press release announcing it has entered into a strategic licensing, collaboration, partnership or similar agreement for the commitment to fund its Phase 3 trials for BPX-01, and (2) the eighteen month anniversary of issuance.
On November 20, 2018, the Company entered into Warrant Exercise Agreements (the “Exercise Agreements”) with the holders of certain of the Existing Warrants (the “Exercising Holders”). Pursuant to the Exercise Agreements, the Exercising Holders and the Company agreed that the Exercising Holders would cash exercise up to 26,666,666 shares of Common Stock underlying such Existing Warrants (the “Exercised Shares”). In order to induce the Exercising Holders to cash exercise the Existing Warrants, the Exercise Agreements (i) amend the Existing Warrants to reduce the exercise price per share of the Existing Warrants to $0.14 (provided that the Existing Warrants are exercised prior to February 28, 2019, otherwise such exercise price shall remain $0.25 per share), and (ii) provide for the issuance of new warrants to purchase up to an aggregate of 26,666,666 shares of Common Stock (the “New Warrants”), with such New Warrants to be issued on a share-for-share basis in an amount equal to the number of shares underlying Existing Warrants that are cash exercised by February 28, 2019. The New Warrants are exercisable after the six-month anniversary of issuance and terminate on the 30-month anniversary following their issuance. The New Warrants have an exercise price per share of $0.164.
The Existing Warrants and Exercised Shares were registered pursuant to the Company’s Registration Statement on Form S-1 (File No. 333-221027), filed with the U.S. Securities and Exchange Commission (“SEC”) under the Securities Act of 1933, as amended (the “Securities Act”) on October 19, 2017, which became effective on November 20, 2017, and the related prospectus dated November 20, 2017.
The New Warrants and the shares of Common Stock issuable upon the exercise of the New Warrants are not being registered under the Securities Act, and are being offered pursuant to the exemption provided in Section 4(a)(2) under the Securities Act.
The Company expects to receive aggregate gross proceeds of up to approximately $3.7 million from the cash exercise of the Existing Warrants by the Exercising Holders.
The Company agreed that, subject to certain exceptions, from today until February 28, 2019 or such earlier date that the Company’s Common Stock’s Closing Sale Price (as defined in the New Warrants) exceeds $0.25 (subject to adjustment for forward and reverse stock splits and the like) for a period of 10 consecutive trading days, neither the Company nor any subsidiary of the Company shall issue, enter into any agreement to issue or announce the issuance of any shares of Common Stock or Common Stock Equivalents (as defined in the Exercise Agreements).
The description of terms and conditions of the Exercise Agreements and the New Warrants set forth herein do not purport to be complete and are qualified in their entirety by reference to the full text of the forms of Exercise Agreement and New Warrant, copies of which are attached as Exhibits 4.1 and 10.1, respectively, to this Current Report on Form 8-K and incorporated herein by reference.
http://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=12563650&type=HTML&symbol=BPMX&companyName=BioPharmX+Corporation.+Common&formType=8-K&dateFiled=2018-11-21
Still sitting on 8,166,102 shares. I come over to this board once in a while looking for hope of some sort of recovery news. I see familiar names from back in the day. Hopefully everyone that was apart of this play back then, is now doing much better these days on their other investments.
To you long timers, thanks for providing updates!
BioPharmX Announces NYSE American Acceptance of Plan To Regain Listing Compliance
MENLO PARK, Calif., Nov. 16, 2018 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX) (the "Company"), a specialty pharmaceutical company developing products for the dermatology market, announced that on November 1, 2018, NYSE Regulation accepted the Company's plan to regain compliance with the NYSE American LLC ("NYSE American") continued listing standards set forth in Sections 1003(a)(iii) of the NYSE American Company Guide. NYSE Regulation has reviewed the Company's compliance plan and has granted a plan period through September 24, 2019.
As previously reported in a Current Report on Form 8-K filed with the Securities and Exchange Commission on November 2, 2018, the Company was notified on September 24, 2018, by NYSE American that the Company was not in compliance with Section 1003(a)(iii) related to stockholders' equity requirements. The Company reported stockholders' equity of $4.3 million as of July 31, 2018 and net losses in its five most recent fiscal years ended January 31, 2018.
This notice from NYSE Regulation has no immediate impact on the listing of the Company's common stock on the NYSE American and the stock will continue to be listed and traded on the NYSE American during the cure period, subject to the Company's compliance with the NYSE American's other applicable continued listing standards. The Company's stock symbol "BPMX" will be assigned a ".BC" indicator by the NYSE American to signify that the Company currently is not in compliance with the NYSE American's continued listing standards. During which time the Company will be subject to periodic review to determine whether the Company is making progress consistent with the accepted plan. If the Company does not make progress consistent with the plan during the plan period, NYSE American may initiate delisting proceedings as appropriate.
Possibly due to the earnings expectations is why it didn't move.
"The company has not been able to beat consensus revenue estimates over the last four quarters."
https://www.google.com/amp/s/www.zacks.com/amp/stock/news/336104/foamix-fomx-reports-q3-loss-lags-revenue-estimates
Nice! Great news to see that Minocycline is providing positive results!
I know the next PR will cause a frenzy here. I would just like to see the price higher and hopefully on an uptrend before the announcement.
Hopefully we are on our way to that type of set up move now.
Nicely done!
LoL, I thought of you after I posted and if you would be chiming in. Yeah, I hear what you mean.
Lests just break past 18 and hold.
GLTY
The "come and short this" alert has been sounded. Question is, will there be enough bull momentum to fight them off?
Could be tough because this move is without news, purely day trade momentum.
Last year was 12/7 after market.
12/7/17
Open .108
High .116
Low .107
Close .1118
12/8/17
Open .1175
High .12
Low .107
Close .1169
Appreciate that! Franklin adding 3.5M shares is really news under the radar. As an institutional investor, I'm sure they see or know more than the common investor. Their move speaks volumes and should boost confidence for longs investors here.
Signs of the share price increase plan coming together for BioPharmX.
So far we've witnessed more of an internal shake-up for the better in the past few weeks, than we've seen from previous president Anja Krammer has done in the past year!
We've seen CEO Tierney cut overhead costs by firing Greg (CFO), Anja (President), and in my opinion, soon to be fired Morlock (who recently, unexpectedly, dumped all of his shares) most likely out of spite knowing the future demise of his position.
Tierney has found a new business location at around half the cost of the past facility, and with a quarterly burn rate of around 4.3M a quarter, it looks like Tierney wants to shave a good bit of costs off the next quarterly earnings report.
Tierney himself has purchased 100,000 shares of the business’s stock to show faith in the company.
Most importantly, Tierney's track record. Here is a CEO that recently led a team at Icon Bioscience, that in 2018 received U.S. FDA approval of its New Drug Application for DEXYCU. Dr. Tierney was president and chief operating officer of Oceana Therapeutics, a specialty therapeutic company he co-founded in 2008 and was later acquired by Salix Pharmaceuticals. In his role as president and chief executive officer of Valera Pharmaceuticals, Tierney raised over $65 million in funding and completed a successful IPO and oversaw NDA approvals of VANTAS and SUPPRELIN LA. In addition to Dr. Tierney’s leadership roles, he has extensive experience in raising capital and has held a position with investment firm, Signet Health Partners.
With a little research of the above mentioned companies, you will find that we now have a CEO with a stellar track record of mergers, acquisitions, and the ability to raise capital. Dr Tierney believes in BioPharmX and the product or he wouldn't have taken on the job. Failure is not an option in his resume!
Work is getting done behind the scenes and Institutional Investors approve!
Most recently a new 13D/A SEC filing in regards to Franklin Advisors and their shares increase of 3.5M since their last 13D/A filing in Dec. 2016 found here.
Here is the link to the most recent 13D/A filing here.
Past president Anja stated that they had many ioi's on the table to secure funding, although she failed to seal the deal. The big investors and original investors had Tierney brought in to save this "Holy Grail" investment that they know carries a superior product over the competition.
Between shake-ups at the higher level and the second largest institutional investor adding, you can't help but notice that positive things are finally getting done in favor for long term investors here! We have been brought down by a lazy, greedy, and incompetent past board of directors that is soon to be shown, has been corrected.
Mr Tierney has his hands full with cleaning up this mess, but as pointed out above, he is working! Remember, he was only brought on 7 weeks ago. I would expect nothing less than an amazing PR announcement to come soon! BioPharmX will be another example to Dr Tierney's stellar resume and track record of performance!
Franklin Correct Increase
Previously owned: 9,749,615
Increased position: 3,551,250
Total shares now: 13,300,865
FRANKLIN RESOURCES INC increased their shares.
Previous shares: 10,019,615
Current shares: 133,008,651
NYSE American’s continued listing standards.
On November 1, 2018, BioPharmX Corporation (“Company”) received a notice from NYSE American LLC (“NYSE American”) that NYSE Regulation reviewed the Company’s compliance plan and determined to accept the plan and grant a plan period through September 24, 2019. NYSE Regulation staff will review the Company periodically for compliance with the initiatives outlined in the plan. If the Company is not in compliance with the NYSE American continued listing standards by September 24, 2019, or if the Company does not make progress consistent with the plan during the plan period, NYSE Regulation staff will initiate delisting proceedings as appropriate. The Company may appeal a staff delisting determination in accordance with Section 1010 and Part 12 of the NYSE American Company Guide.
On September 24, 2018, the Company received a notice from the NYSE American that the Company was not in compliance with the stockholders’ equity requirement as forth in Part 10 of the NYSE American Company Guide. The Company reported stockholders’ equity of $4.3 million as of July 31, 2018 and net losses in its five most recent fiscal years ended January 31, 2018.
The Company’s common stock will continue to be listed and traded on the NYSE American during the cure period, subject to the Company’s compliance with the NYSE American’s other applicable continued listing standards. The Company’s stock symbol “BPMX” will be assigned a “.BC” indicator by the NYSE American to signify that the Company currently is not in compliance with the NYSE American’s continued listing standards.
CEO Tierney still cutting overhead costs. Looks like a move from the expensive BayArea Menlo Park, CA to a more affordable location in San Jose.
Tierney still "Trimming the Fat"
On October 30, 2018, BioPharmX, Inc., a wholly-owned subsidiary of BioPharmX Corporation (the “Company”), and The Irvine Company LLC, entered into a Lease Agreement (“Lease”) for the lease of approximately 11,793 square feet of office and laboratory space located at 115 Nicholson Lane, San Jose, California, which will replace the Company’s current corporate headquarters. This facility will serve as the new principal executive office and laboratory for the Company. The term of the lease is for 5 years commencing on or about December 11, 2018.
As for me, you can go back and read my posts. I've been invested with BPMX since 2014, so sure, in the beginning I was completely behind management before they took us off the path of research and development and into marketing, which they are not built to do.
I'm thinking most people who invest want to stand behind management and their investment, protect it so to speak, so that's where you will see much praise towards Anja and the team.
The BS going on that you mention is definitely frustration with the stock price and how the last BioPharmX board lead us to where we are at now. We have to give Tierney time to straighten things out .
With Morlock selling shares recently, I think Tierney is still working on cleaning up the mess the last board members left behind. Surprised we haven't seen Morlock get the boot yet, so that's why I think the house cleaning isn't complete.
Unfortunately as we've waited for news, the stock has broken through the support line, so I anticipate a few more pennies to fall off until next support is reached. Without news, all we can rely on is a day trader's rally off the next support.
Make no mistake about it though, Tierney has been brought in to get this company back on track! Just look at his resume. He's only been with us a few weeks and already has accomplish cutting out the companies biggest downfall, Anja and Kichener! I'm sure Morlock is next, and that's why he tried sabotaging us by selling off his shares.
So looking at the big picture, Tierney is cutting company expenses! He's trimming the fat and we've yet to see the dessert menu! I see a real nice future PR coming together! I have full confidence in this new CEO and feel better about my investment than I have in years!
So now Morlock sells...
I'll be looking for that termination letter soon for Morlock, otherwise, WTH?
Tierney, we need some answers! What's going on with this board of directors? Hopefully your just cleaning up their mess of just sitting around and doing nothing these past years! Cleaning house so to speak. Looking forward to seeing your SEC compliance letter update!
POS board members anyway! Did nothing for Investors! Only looked out for themselves collecting shareholders money as we fell lower and lower! Let those ioi's collect dust because they didn't include themselves in the deal of moving forward! Good riddance if firing is the case!!
I guess they forgot to ask her why the hell she decided to sell shares at this price level when her 1.2M dollar salary should've easily covered $95k. Still making dumb decisions I guess as she kicks us investors while we're down one more time for good measure...
There is definitely explosive news to come on the horizon, although I don't think a dollar will be achievable by the end of the year. Don't get me wrong, I want nothing more than to break above a dollar, although I believe we need to get closer to the end of phase 3 for BPX-01, FDA advancements, undisclosed developments, and completion of BPX-04 Rosacea to push us over the dollar mark. All of that is more likely to start happening after the first quarter of 2019. I hope I'm wrong though By the way, there is heavy resistance around .89 if you look back a few years on the chart.
I'm looking for nice bump on funding news and the start of phase 3, then a nice steady climb towards all the above mentioned.
GLTY!
Only speculating thoughts I believe in this order.
1) She has cash on hand for her next gig. Maybe she's moving to another company where she will want to buy shares with them.
2) Maybe BioPharmX wanted her to reduce shares to lesson her voting rights per new terms of the deal that's being set up between BioPharmX and partner. (far-fetched guess)
3) Spite, sold out of frustration, although I don't really believe that is the reason.
Either way, BioPharmX is better off!! We are about to get moving up with David Tierney (the closer) in there now. I believe Anja got greedy and was looking out for herself instead of what was best for shareholders and institutional holders. Thats why she never signed a deal and dragged us through a year plus of wasted time and value. I'm sure these deals didn't include her so she never accepted them, so the institutional investors applied pressure for this change. I would think that any new Investors willing to put up funding for BioPharmX wanted to have their own people on board and that was a threat to her cushy situation. We are way better off now! Just waiting for that funding/phase 3 announcement!!
Foamix to Present Clinical Data From Study FX2017-22 at the Fall Clinical Dermatology Conference
REHOVOT, Israel and BRIDGEWATER, N.J., Oct. 12, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology, today announced that data from its Phase 3 clinical trial, FX2017-22, which investigated FMX101 for the treatment of moderate-to-severe acne, will be presented at the Fall Clinical Dermatology Conference to be held October 18 – 21 at the Wynn Hotel in Las Vegas, Nevada.
The poster, which is entitled “FMX101 4% Topical Minocycline Foam for the Treatment of Moderate-to-Severe Acne Vulgaris: Efficacy and Safety From a Phase 3 Randomized, Double-Blind, Vehicle-Controlled Study” is expected to be presented during several plenary and scientific poster sessions throughout the conference. A copy of the poster will be available on the Foamix corporate website http://foamix.com/, simultaneous with its presentation at the conference.
As the company previously communicated, the Phase 3 study met both co-primary endpoints of (1) absolute change from baseline in inflammatory lesion count at Week 12, and (2) Investigator Global Assessment (“IGA”) treatment success at Week 12, defined as an IGA score of 0 or 1, and at least a 2-grade improvement (decrease) from baseline. Results from both co-primary endpoints demonstrated highly statistically significant results for FMX101 vs vehicle, with p-values <0.0001. The favorable safety profile of FMX101 was consistent with that determined from the two prior Phase 3 studies of FMX101 in acne (FX2014-04 and FX2014-05).
About the Fall Clinical Dermatology Conference
The Fall Clinical Dermatology Conference® Las Vegas is a four-day program designed to provide the practicing dermatologist with a comprehensive update on the diagnosis and treatment of a variety of conditions related to medical, surgical and cosmetic dermatology. For additional information, refer to https://fallclinical.health/conferences/fall-clinical-2018/.
My honest opinion, Jim Perkarsky, original CEO, is the true person who set the company into motion, hit cruise control and Anja just held the wheel from there and literally drove us into the ditch!
Not as bad as she did us shareholders! We should have already been through phase 3 for BPX-01, had funding secured, and have moved on to new development, although here we are! Scraping the bottom in share price, more than a year behind schedule, and twice as much diluted as we were a little over a year ago! The company was being mismanaged, but we're on track now with David at the helm!
We're back in focus now! Looking forward to the secured funding news next!
Most intelligent post I read today.
"88tommygunzzz88Oct 11th, 2:32 pm
Anja was a founder of the company don’t see her just getting fired for no good reason partner wants things how they want them"
Excellent insight!
What's next? Next comes the funding. Anja was just letting those ioi's collect dust on her desk! She had no intention of partnering while she enjoyed her 1.2 million salary. She honestly cost us Investors over a year of wasted time!
David Tierney is here to follow through with the original plans of this research and development company! We are finally getting back on track! Big moves coming next!!
BioPharmX board appointed Joyce Goto, age 45, the Company’s Vice President and Controller, to serve as the Principal Accounting Officer, effective October 10, 2018. Ms. Goto has served as the Company’s Vice President and Controller since April 2015. There are no family relationships between Ms. Goto and any previous or current officers or directors of the Company, and there are no related party transactions reportable under Item 404(a) of Regulation S-K.